SELLAS Life Sciences Group Inc (SLS)

[crudeoil24]

The update call on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) is on November 14, 2022.


The call will be facilitated by SELLAS management, including SELLAS' President and CEO, Angelos Stergiou, MD, ScD h.c., and Senior Vice President, Clinical Development, Dragan Cicic, MD, who will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies Research at the Baylor University Medical Center, and member of the REGAL Steering Committee. Further details regarding how to access the update call will be provided in the coming weeks.